First human test of new melanoma drug cocktail
NCT ID NCT04640545
Summary
This early-stage study tested the safety of a new three-drug combination (LBL-007, toripalimab, and axitinib) for people with advanced melanoma that cannot be removed by surgery. The main goal was to find the highest safe dose and see what side effects occurred. Researchers also looked for early signs that the treatment could help shrink or control tumors.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED MELANOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Beijing Cancer Hospital
Beijing, Beijing Municipality, 100142, China
-
Fujian Cancer Hospital
Fuzhou, Fujian, 350000, China
-
Hunan Cancer Hospital
Changsha, Hunan, 410006, China
-
Jilin Cancer Hospital
Changchun, Jilin, 130021, China
-
Nanjing Drum Tower Hospital
Nanjing, Jiangsu, 210008, China
-
Union Hospital Tongji Medical College Huazhong University of Science and Technology
Wuhan, Hubei, 430022, China
-
West China Hospital of Sichuan University
Chengdu, Sichuan, 610041, China
-
the First Hospital of Jilin University
Changchun, Jilin, 130021, China
Conditions
Explore the condition pages connected to this study.